关注
Alexey V. Sorokin
Alexey V. Sorokin
在 mdanderson.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition
V Evdokimova, C Tognon, T Ng, P Ruzanov, N Melnyk, D Fink, A Sorokin, ...
Cancer cell 15 (5), 402-415, 2009
5462009
Nucleocytoplasmic transport of proteins
AV Sorokin, ER Kim, LP Ovchinnikov
Biochemistry (Moscow) 72, 1439-1457, 2007
3502007
Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species
V Evdokimova, P Ruzanov, MS Anglesio, AV Sorokin, LP Ovchinnikov, ...
Molecular and cellular biology 26 (1), 277-292, 2006
3212006
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, ...
Cancer discovery 6 (12), 1352-1365, 2016
2342016
Proteasome system of protein degradation and processing
AV Sorokin, ER Kim, LP Ovchinnikov
Biochemistry (Moscow) 74, 1411-1442, 2009
2242009
Proteasome‐mediated cleavage of the Y‐box‐binding protein 1 is linked to DNA‐damage stress response
AV Sorokin, AA Selyutina, MA Skabkin, SG Guryanov, IV Nazimov, ...
The EMBO journal 24 (20), 3602-3612, 2005
1962005
Structural organization of mRNA complexes with major core mRNP protein YB-1
MA Skabkin, OI Kiselyova, KG Chernov, AV Sorokin, EV Dubrovin, ...
Nucleic acids research 32 (18), 5621-5635, 2004
1952004
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
S Kopetz, KA Guthrie, VK Morris, HJ Lenz, AM Magliocco, D Maru, Y Yan, ...
Journal of Clinical Oncology 39 (4), 285, 2021
1902021
The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA-damaging stress
ER Kim, AA Selyutina, IA Buldakov, V Evdokimova, LP Ovchinnikov, ...
Cell Cycle 12 (24), 3791–3803, 2013
822013
MEMO1, a new IRS1-interacting protein, induces epithelial–mesenchymal transition in mammary epithelial cells
AV Sorokin, J Chen
Oncogene 32 (26), 3130-3138, 2013
762013
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
H Sun, S Cao, RJ Mashl, CK Mo, S Zaccaria, MC Wendl, SR Davies, ...
Nature communications 12 (1), 5086, 2021
752021
Протеасомная система деградации и процессинга белков
АВ Сорокин, ЕР Ким, ЛП Овчинников
Успехи биологической химии 49, 3-76, 2009
632009
Defining the protein-protein interaction network of the human protein tyrosine phosphatase family
X Li, KM Tran, KE Aziz, AV Sorokin, J Chen, W Wang
Molecular & Cellular Proteomics 15 (9), 3030-3044, 2016
562016
KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
MB Ryan, O Coker, A Sorokin, K Fella, H Barnes, E Wong, P Kanikarla, ...
Cell reports 39 (12), 2022
502022
Modeling of patient-derived xenografts in colorectal cancer
A Katsiampoura, K Raghav, ZQ Jiang, DG Menter, A Varkaris, MP Morelli, ...
Molecular cancer therapeutics 16 (7), 1435-1442, 2017
482017
Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 2016; 6: 1352 …
DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, ...
DOI: https://doi. org/10.1158/2159-8290. CD-16-0050. PMID: https://www. ncbi …, 0
40
Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells
AV Vaiman, TP Stromskaya, EY Rybalkina, AV Sorokin, SG Guryanov, ...
Biochemistry (Moscow) 71, 146-154, 2006
392006
Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer
E Orouji, AT Raman, AK Singh, A Sorokin, E Arslan, AK Ghosh, J Schulz, ...
Gut 71 (5), 938-949, 2022
312022
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
S Napolitano, N Matrone, AL Muddassir, G Martini, A Sorokin, V De Falco, ...
Journal of Experimental & Clinical Cancer Research 38, 1-18, 2019
312019
Platelet metabolism and other targeted drugs; potential impact on immunotherapy
P Kanikarla-Marie, M Lam, AV Sorokin, MJ Overman, S Kopetz, ...
Frontiers in Oncology 8, 107, 2018
302018
系统目前无法执行此操作,请稍后再试。
文章 1–20